Who
Dipal Doshi
CEO
Company insider
Files Form 4 as: CEO, Entrada Therapeutics; Director, Azenta; SVP Strategy & Bus Dev, Amicus Therapeutics.
In numbers
- Trades disclosed
- 99
- Buys
- 0
- Sells
- 41
- Bought
- $0
- Sold
- $1.5M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 7 Jul 2014
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $62K8,724 at $7.14 | filing |
| 2 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $62K8,724 at $7.14 | filing |
| 3 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $225K19,181 at $11.76 | filing |
| 3 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $226K19,181 at $11.76 | filing |
| 2 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $115K9,869 at $11.66 | filing |
| 2 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $115K9,869 at $11.66 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —139,400 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —208,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —208,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —139,400 at $0.00 | filing |
| 5 Feb 2026filed 6 Feb 2026 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | $158K5,663 at $27.85 | filing |
| 5 Feb 2026filed 6 Feb 2026 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | $158K5,663 at $27.85 | filing |
| 2 Sep 2025filed 4 Sep 2025 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $47K8,723 at $5.43 | filing |
| 3 Mar 2025filed 4 Mar 2025 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $205K17,566 at $11.68 | filing |
| 1 Mar 2025filed 4 Mar 2025 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —173,400 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —116,200 at $0.00 | filing |
| 7 Feb 2025filed 11 Feb 2025 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | $211K4,040 at $52.32 | filing |
| 5 Sep 2024filed 5 Sep 2024 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $12K826 at $15.13 | filing |
| 4 Sep 2024filed 5 Sep 2024 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $73K4,744 at $15.42 | filing |
| 3 Sep 2024filed 5 Sep 2024 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $37K2,328 at $15.76 | filing |
News
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45TRDA · manilatimes.net · 14 Oct 2026Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyTRDA · manilatimes.net · 14 Oct 2026Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)TRDA · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Dipal Doshi; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.